Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation

Mansfield, Carol A.; Metcalfe, Kelly A.; Snyder, Carrie; Lindeman, Geoffrey J.; Posner, Joshua; Friedman, Sue; Lynch, Henry T.; Narod, Steven A.; Evans, D. Gareth; Liede, Alexander

doi:10.1186/s13053-020-00152-z

Hereditary Cancer in Clinical Practice

Table 2 Responses to Treatment Sequencing Questions (N = 598, unless otherwise noted)

From: Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation

Summaries	Treatment Option	Value, n (%)
Respondent’s treatment selection for themselves^a
Treatment option ever selected as part of treatment sequence	RRBM	441 (73.7)
	RRBSO	470 (78.6)
	Medicine (Medicine 1 or Medicine 2)	178 (29.8)
Among respondents assigned to Medicine 1^b
	n	289
	Medicine 1	90 (31.1)
Among respondents assigned to Medicine 2^b
	n	309
	Medicine 2	88 (28.5)
Treatment advice for Susan, age 25 years or age 36 years^a
Among respondents assigned to Susan, age 25 years^c
Treatment option ever selected as part of the Susan treatment sequence	n^d	285
	RRBM	157 (55.1)
	RRBSO	110 (38.6)
	Medicine 1	87 (30.5)
Among respondents assigned to Susan, age 36 years^c
Treatment option ever selected as part of the Susan treatment sequence	n^e	302
	RRBM	214 (70.9)
	RRBSO	147 (48.7)
	Medicine 2	68 (22.5)

ONJ Osteonecrosis of the jaw, RRBM Risk-reducing bilateral mastectomy, RRBSO Bilateral salpingo oophorectomy
^aRespondents were asked to think back to when they first discovered their BRCA1 or BRCA2 mutation and to assume that the 4 choices presented in Fig. 1a/1b were all available. They were then asked to select the first action they would take if the four options presented were their only choices. The survey directed respondents who selected screening only to indicate how long they would screen before moving on to another treatment. Respondents were asked to continue reporting their treatment choices in sequence until they reached the point at which they would choose not to take any additional action, and to continue only with screening. Respondents were then asked to make the same choices for Susan, age 25 or Susan, age 36; a hypothetical woman described on the Methods section
^bRespondents were randomly assigned to either Medicine 1 (50% breast cancer risk reduction, take for 3 years, cannot get pregnant during treatment, no effect on female hormone levels, 5% risk of ONJ, no risk of uterine cancer, injection at doctor’s office every 3 months) or Medicine 2 (40% breast cancer risk reduction, take for 5 years, cannot get pregnant during treatment, temporary menopause-like symptoms, no risk of ONJ, 1% risk of uterine cancer, daily pill)
^cAll respondents assigned to Susan, age 25 years, were assigned to view Medicine 1; all respondents assigned to Susan, age 36 years, were assigned to Medicine 2
^d289 were assigned; 285 answered these treatment-sequencing questions. Thus all are not included in the sample total
^e306 were assigned; 302 answered these treatment-sequencing questions. Of the 309 respondents eligible because they were assigned to Medicine 2, 3 did not complete the full survey and are not included in the sample total

Back to article page

ISSN: 1897-4287

Contact us

General enquiries: journalsubmissions@springernature.com